Development of an ultra-compact proton cancer therapy system

Ultra-compact proton cancer therapy device" Proton therapy is a treatment that uses the physical properties of protons to pinpoint tumors deep inside the body, thereby minimizing damage to normal tissues and organs. Bidot Medical has developed a proton therapy device that is significantly smaller and less expensive than conventional devices based on groundbreaking technology, and is aiming to realize a society in which anyone can receive proton therapy.
Investment Background
Although proton beam therapy is an advanced medical treatment that is expected to become more widespread in the future, its introduction into hospitals has been hindered by the huge size and high cost of the equipment. Beadt Medical's device has achieved a significant reduction in size, making it possible to offer a new alternative to the widely used X-ray therapy equipment. It is hoped that this unique approach will promote the spread of proton therapy.
About Beadt Medical, Inc.
| name of company | Beadt Medical, Inc. |
| Establishment | March 1, 2017 |
| Location | 5-10-10 Harue-cho, Edogawa-ku, Tokyo |
| representative | Takuji Furukawa |
| Business Overview | Development of proton beam cancer therapy equipment, consulting related to particle beam cancer therapy, etc. |
| uniform resouce locator | https://bdotmed.co.jp/ |
About Mitsubishi UFJ Capital Co.

Since its establishment in 1974, Mitsubishi UFJ Capital has provided industry-leading expertise as the venture capital arm of Mitsubishi UFJ Financial Group and has invested in a wide range of industries. The number of companies that have achieved IPOs is approximately 900 across a wide range of industries.
In the life science field, after the establishment of the Life Science Office in 2009, we began providing funding and management support to bio ventures in Japan and overseas in earnest. In 2017, we established the Life Science Department and also created our first industry-specific fund, Mitsubishi UFJ Life Science No. 1 Investment Business In February 2019, Mitsubishi UFJ Life Science No. 2 Investment Limited Partnership (10 billion yen) was formed, and in June 2020, MUFG Medical Fund (10 billion yen) was formed to support venture companies involved in drug discovery and regenerative medicine, including measures against new-type coronary infections. In addition to bio-venture investments, MUFG is focusing on investments in academia drug discovery, carve-outs of pharmaceutical companies, investments in development projects of pharmaceutical companies, and medical device-related investments.
| name of company | Mitsubishi UFJ Capital Co. |
| Establishment | August 1, 1974 |
| Location | Nihonbashi Plaza Building 7F, 2-3-4 Nihonbashi, Chuo-ku, Tokyo |
| representative | Shinsuke Sakamoto |
| Business Overview | Venture Capital Business |
| uniform resouce locator | https://www.mucap.co.jp/ |
■MUFG Medical Fund (official name: Mitsubishi UFJ Life Science No. 3 Investment Limited Partnership))About
Investment TargetPharmaceuticals (Drug Discovery Type, Drug Discovery Basic Technology Specialized Type)
Focus on investment activities in pharmaceutical companies and academia drug discovery in Japan
regenerative medicine products
Medical equipment, etc.
Diagnostics and diagnostic equipment
unlimited partnersMitsubishi UFJ Capital Co.
investorThe Bank of Tokyo-Mitsubishi UFJ, Ltd. and Mitsubishi UFJ Capital Co.
Date of EstablishmentJune 22, 2020
Total amount of funds10 billion yen









